HIV相关性周围神经病诊治进展
|
摘要
周围神经病是人类免疫缺陷病毒(human immunodeficiency virus, HIV)感染者最常见的神经系统疾病,临床表现以远端对称性周围神经病、急性炎症性脱髓鞘性多发性神经病或慢性炎症性脱髓鞘性多发性神经病及多发性单神经病最为常见,严重影响患者的生活质量。本文旨在通过分析HIV相关性周围神经病(HIV peripheral neuropathy,HIV-PN)的病理生理变化及发病机制,深入了解HIV-PN的临床表现,总结其诊治经验,从而指导临床医师正确认识、合理预防、规范诊治该病。
Peripheral neuropathy is the most common neurological disease in HIV-infected people. Distal symmetrical peripheral neuropathy, acute inflammatory demyelinating polyneuropathy, chronic inflammatory demyelinating polyneuropathy and mononeuropathy multiplex are the most common clinical complications, which seriously affect life quality of patients. This article aims to analyze the pathophysiological changes and pathogenesis of HIV peripheral neuropathy(HIV-PN), to understand the clinical manifestations of HIV-PN, and to summarize its experience in diagnosis and treatment, so as to guide clinicians to correctly understand, reasonable prevent the disease, and standardize the diagnosis and treatment.
Peripheral neuropathy is the most common neurological disease in HIV-infected people. Distal symmetrical peripheral neuropathy, acute inflammatory demyelinating polyneuropathy, chronic inflammatory demyelinating polyneuropathy and mononeuropathy multiplex are the most common clinical complications, which seriously affect life quality of patients. This article aims to analyze the pathophysiological changes and pathogenesis of HIV peripheral neuropathy(HIV-PN), to understand the clinical manifestations of HIV-PN, and to summarize its experience in diagnosis and treatment, so as to guide clinicians to correctly understand, reasonable prevent the disease, and standardize the diagnosis and treatment.
引文
[1] 吴尊友. 我国艾滋病经性传播新特征与防治面临的挑战[J].中华流行病学杂志,2018,39(6):707-709.
[2] Evans SR, Ellis RJ, Chen H, et al. Peripheral neuropathy in HIV:prevalence and risk factors[J]. AIDS, 2011, 25(7):919-928.
[3] Centner CM, Little F, Van Der Watt JJ, et al. Evolution of sensory neuropathy after initiation of antiretroviral therapy[J]. Muscle Nerve,2018, 57(3):371-379.
[4] Ghosh S, Chandran A, Jansen JP. Epidemiology of HIV-related neuropathy: a systematic literature review[J]. AIDS Res Hum Retroviruses, 2012, 28(1):36-48.
[5] Chen H, Clifford DB, Deng L, et al. Peripheral neuropathy in ART-experienced patients: prevalence and risk factors[J]. J Neurovirol, 2013, 19(6):557-564.
[6] Benevides ML, Filho SB, Debona R, et al. Prevalence of peripheral neuropathy and associated factors in HIV-infected patients[J]. J Neurol Sci, 2017, 375:316-320.
[7] Banerjee S, McCutchan JA, Ances BM, et al. Hypertriglyceridemia in combination antiretroviral-treated HIV-positive individuals: potential impact on HIV sensory polyneuropathy[J]. AIDS, 2011, 25(2): F1-6.
[8] Robinson-Papp J, Gelman BB, Grant I, et al. Substance abuse increases the risk of neuropathy in an HIV-infected cohort[J]. Muscle Nerve, 2012, 45(4):471-476.
[9] Van der Watt JJ, Harrison TB, Benatar M, et al. Polyneuropathy, anti-tuberculosis treatment and the role of pyridoxine in the HIV/AIDS era: a systematic review[J]. Int J Tuberc Lung Dis, 2011, 15(6):722-728.
[10] Kaku M, Simpson DM. HIV, antiretrovirals, and peripheral neuropathy: A moving target[J]. Muscle Nerve, 2018, 57(3):347-349.
[11] Hao S. The molecular and pharmacological mechanisms of HIV-related neuropathic pain[J]. Curr Neuropharmacol, 2013, 11(5):499-512.
[12] Nasirinezhad F, Jergova S, Pearson JP, et al. Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy[J]. Neuropharmacology, 2015, 95:100-109.
[13] Yuan SB, Shi Y, Chen J, et al. gp120 in the pathogenesis of human immunodeficiency virus-associated pain[J]. Ann Neurol, 2014, 75(6):837-850.
[14] Zheng W, Huang W, Liu S, et al. Interleukin 10 mediated by herpes simplex virus vectors suppresses neuropathic pain induced by human immunodeficiency virus gp120 in rats[J]. Anesth Analg, 2014, 119(3):693-701.
[15] Kamerman PR, Moss PJ, Weber J, et al. Pathogenesis of HIV-associated sensory neuropathy: Evidence from in vivo and in vitro experimental models[J]. J Peripher Nerv Syst, 2012, 17(1):19-31.
[16] 孙玉, 栾森, 张洪海, 等. P53凋亡刺激蛋白2在gp120诱导的神经细胞凋亡中的作用[J].临床荟萃, 2013, 28(11):1207-1209.
[17] Chauhan P, Sheng WS, Hu S, et al. Nitrosative damage during retrovirus infection-induced neuropathic pain[J]. J Neuroinflammation, 2018, 15(1):66.
[18] Ellis RJ, Rosario D, Clifford DB, et al. Continued high prevalence and adverse clinical impact of human immunodeficiency virusassociated sensory neuropathy in the era of combination antiretroviral therapy: The CHARTER study[J]. Arch Neurol, 2010, 67(5):552-558.
[19] Lehmann HC, Chen W, Borzan J, et al. Mitochondrial dysfunction in distal axons contributes to human immunodeficiency virus sensory neuropathy[J]. Ann Neurol, 2011, 69(1):100-110.
[20] Robinson-Papp J, Sharma S, Simpson DM, et al. Autonomic dysfunction is common in HIV and associated with distal symmetric polyneuropathy[J]. J Neurovirol, 2013, 19(2):172-180.
[21] Kaku M, Simpson DM. HIV neuropathy[J]. Curr Opin HIV AIDS, 2014, 9(6):521-526.
[22] Biraguma J, Rhoda A. Peripheral neuropathy and quality of life of adults living with HIV/AIDS in the Rulindo district of Rwanda[J]. SAHARA J, 2012, 9(2):88-94.
[23] Finney KA, David L. Brachial plexus neuritis in the context of acute HIV seroconversion illness: a case report[J]. Int J STD AIDS, 2012, 23(2):143-144.
[24] Robinson-Papp J, Sharma SK. Autonomic neuropathy in HIV is unrecognized and associated with medical morbidity[J]. AIDS Patient Care STDS, 2013, 27(10):539-543.
[25] Mawuntu AHP, Mahama CN, Khosama H, et al. Early detection of peripheral neuropathy using stimulated skin wrinkling test in human immunodeficiency virus infected patients: A cross-sectional study[J]. Medicine (Baltimore), 2018, 97(30):e11526.
[26] Merola A, Rosso M, Romagnolo A, et al. Peripheral nerve ultrasonography in chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: correlations with clinical and neurophysiological data[J]. Neurol Res Int, 2016, 2016:9478593.
[27] World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach[EB/OL]. https://www.who.int/hiv/pub/guidelines/arv2013/download/en/. 2013-01-30
[28] World Health Organization. March 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach[EB/OL]. https://www.who.int/hiv/pub/guidelines/arv2013/arvs2013upplement_march2014/en/. 2014-05.
[29] Cherry CL, Wadley AL, Kamerman PR. Diagnosing and treating HIV-associated sensory neuropathy: a global perspective[J]. Pain Manag, 2016, 6(2):191-199.
[30] Lucey BP, Cliff ord DB, Creighton J, et al. Relationship of depression and catastrophizing to pain, disability, and medication adherence in patients with HIV-associated sensory neuropathy[J]. AIDS Care, 2011, 23(8):921-928.
[31] Cepeda MS, Berlin JA, Gao CY, et al. Placebo response changes depending on the neuropathic pain syndrome: results of a systematic review and meta-analysis[J]. Pain Med, 2012, 13(4):575-795.
[32] Phillips TJ, Cherry CL, Cox S, et al. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomized controlled trials[J]. PLoS One, 2010, 5(12):e14433.
[33] Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial[J]. Neuropsychopharmacology, 2009, 34(3):672-680.
[34] Simpson DM, Brown S, Tobias JK, et al. NGX-4010, a capsaicin 8 % dermal patch, for the treatment of painful HIVassociated distal sensory polyneuropathy: results of a 52-week open-label study[J]. Clin J Pain, 2014, 30(2):134-142.
[35] Bhatia NS, Chow FC. Neurologic complications in treated HIV-1 infection[J]. Curr Neurol Neurosci Rep, 2016, 16(7):62.
[36] Dimitrova A, Murchison C, Oken B. Acupuncture for the treatment of peripheral neuropathy: a systematic review and meta-analysis[J]. J Altern Complement Med, 2017, 23(3):164-179.
[37] Dorfman D, George MC, Schnur J, et al. Hypnosis for treatment of HIV neuropathic pain: a preliminary report[J]. Pain Med, 2013, 14(7): 1048-1056.
[38] Mkandla K, Myezwa H, Musenge E. The effects of progressive-resisted exercises on muscle strength and health-related quality of life in persons with HIV-related poly-neuropathy in Zimbabwe[J]. AIDS Care, 2016, 28(5):639-643.
[39] Sandoval R, Roddey T, Giordano TP, et al. Randomized trial of lower extremity splinting to manage neuropathic pain and sleep disturbances in people living with HIV/AIDS[J]. J Int Assoc Provid AIDS Care, 2016, 15(3):240-247.
[2] Evans SR, Ellis RJ, Chen H, et al. Peripheral neuropathy in HIV:prevalence and risk factors[J]. AIDS, 2011, 25(7):919-928.
[3] Centner CM, Little F, Van Der Watt JJ, et al. Evolution of sensory neuropathy after initiation of antiretroviral therapy[J]. Muscle Nerve,2018, 57(3):371-379.
[4] Ghosh S, Chandran A, Jansen JP. Epidemiology of HIV-related neuropathy: a systematic literature review[J]. AIDS Res Hum Retroviruses, 2012, 28(1):36-48.
[5] Chen H, Clifford DB, Deng L, et al. Peripheral neuropathy in ART-experienced patients: prevalence and risk factors[J]. J Neurovirol, 2013, 19(6):557-564.
[6] Benevides ML, Filho SB, Debona R, et al. Prevalence of peripheral neuropathy and associated factors in HIV-infected patients[J]. J Neurol Sci, 2017, 375:316-320.
[7] Banerjee S, McCutchan JA, Ances BM, et al. Hypertriglyceridemia in combination antiretroviral-treated HIV-positive individuals: potential impact on HIV sensory polyneuropathy[J]. AIDS, 2011, 25(2): F1-6.
[8] Robinson-Papp J, Gelman BB, Grant I, et al. Substance abuse increases the risk of neuropathy in an HIV-infected cohort[J]. Muscle Nerve, 2012, 45(4):471-476.
[9] Van der Watt JJ, Harrison TB, Benatar M, et al. Polyneuropathy, anti-tuberculosis treatment and the role of pyridoxine in the HIV/AIDS era: a systematic review[J]. Int J Tuberc Lung Dis, 2011, 15(6):722-728.
[10] Kaku M, Simpson DM. HIV, antiretrovirals, and peripheral neuropathy: A moving target[J]. Muscle Nerve, 2018, 57(3):347-349.
[11] Hao S. The molecular and pharmacological mechanisms of HIV-related neuropathic pain[J]. Curr Neuropharmacol, 2013, 11(5):499-512.
[12] Nasirinezhad F, Jergova S, Pearson JP, et al. Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy[J]. Neuropharmacology, 2015, 95:100-109.
[13] Yuan SB, Shi Y, Chen J, et al. gp120 in the pathogenesis of human immunodeficiency virus-associated pain[J]. Ann Neurol, 2014, 75(6):837-850.
[14] Zheng W, Huang W, Liu S, et al. Interleukin 10 mediated by herpes simplex virus vectors suppresses neuropathic pain induced by human immunodeficiency virus gp120 in rats[J]. Anesth Analg, 2014, 119(3):693-701.
[15] Kamerman PR, Moss PJ, Weber J, et al. Pathogenesis of HIV-associated sensory neuropathy: Evidence from in vivo and in vitro experimental models[J]. J Peripher Nerv Syst, 2012, 17(1):19-31.
[16] 孙玉, 栾森, 张洪海, 等. P53凋亡刺激蛋白2在gp120诱导的神经细胞凋亡中的作用[J].临床荟萃, 2013, 28(11):1207-1209.
[17] Chauhan P, Sheng WS, Hu S, et al. Nitrosative damage during retrovirus infection-induced neuropathic pain[J]. J Neuroinflammation, 2018, 15(1):66.
[18] Ellis RJ, Rosario D, Clifford DB, et al. Continued high prevalence and adverse clinical impact of human immunodeficiency virusassociated sensory neuropathy in the era of combination antiretroviral therapy: The CHARTER study[J]. Arch Neurol, 2010, 67(5):552-558.
[19] Lehmann HC, Chen W, Borzan J, et al. Mitochondrial dysfunction in distal axons contributes to human immunodeficiency virus sensory neuropathy[J]. Ann Neurol, 2011, 69(1):100-110.
[20] Robinson-Papp J, Sharma S, Simpson DM, et al. Autonomic dysfunction is common in HIV and associated with distal symmetric polyneuropathy[J]. J Neurovirol, 2013, 19(2):172-180.
[21] Kaku M, Simpson DM. HIV neuropathy[J]. Curr Opin HIV AIDS, 2014, 9(6):521-526.
[22] Biraguma J, Rhoda A. Peripheral neuropathy and quality of life of adults living with HIV/AIDS in the Rulindo district of Rwanda[J]. SAHARA J, 2012, 9(2):88-94.
[23] Finney KA, David L. Brachial plexus neuritis in the context of acute HIV seroconversion illness: a case report[J]. Int J STD AIDS, 2012, 23(2):143-144.
[24] Robinson-Papp J, Sharma SK. Autonomic neuropathy in HIV is unrecognized and associated with medical morbidity[J]. AIDS Patient Care STDS, 2013, 27(10):539-543.
[25] Mawuntu AHP, Mahama CN, Khosama H, et al. Early detection of peripheral neuropathy using stimulated skin wrinkling test in human immunodeficiency virus infected patients: A cross-sectional study[J]. Medicine (Baltimore), 2018, 97(30):e11526.
[26] Merola A, Rosso M, Romagnolo A, et al. Peripheral nerve ultrasonography in chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: correlations with clinical and neurophysiological data[J]. Neurol Res Int, 2016, 2016:9478593.
[27] World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach[EB/OL]. https://www.who.int/hiv/pub/guidelines/arv2013/download/en/. 2013-01-30
[28] World Health Organization. March 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach[EB/OL]. https://www.who.int/hiv/pub/guidelines/arv2013/arvs2013upplement_march2014/en/. 2014-05.
[29] Cherry CL, Wadley AL, Kamerman PR. Diagnosing and treating HIV-associated sensory neuropathy: a global perspective[J]. Pain Manag, 2016, 6(2):191-199.
[30] Lucey BP, Cliff ord DB, Creighton J, et al. Relationship of depression and catastrophizing to pain, disability, and medication adherence in patients with HIV-associated sensory neuropathy[J]. AIDS Care, 2011, 23(8):921-928.
[31] Cepeda MS, Berlin JA, Gao CY, et al. Placebo response changes depending on the neuropathic pain syndrome: results of a systematic review and meta-analysis[J]. Pain Med, 2012, 13(4):575-795.
[32] Phillips TJ, Cherry CL, Cox S, et al. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomized controlled trials[J]. PLoS One, 2010, 5(12):e14433.
[33] Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial[J]. Neuropsychopharmacology, 2009, 34(3):672-680.
[34] Simpson DM, Brown S, Tobias JK, et al. NGX-4010, a capsaicin 8 % dermal patch, for the treatment of painful HIVassociated distal sensory polyneuropathy: results of a 52-week open-label study[J]. Clin J Pain, 2014, 30(2):134-142.
[35] Bhatia NS, Chow FC. Neurologic complications in treated HIV-1 infection[J]. Curr Neurol Neurosci Rep, 2016, 16(7):62.
[36] Dimitrova A, Murchison C, Oken B. Acupuncture for the treatment of peripheral neuropathy: a systematic review and meta-analysis[J]. J Altern Complement Med, 2017, 23(3):164-179.
[37] Dorfman D, George MC, Schnur J, et al. Hypnosis for treatment of HIV neuropathic pain: a preliminary report[J]. Pain Med, 2013, 14(7): 1048-1056.
[38] Mkandla K, Myezwa H, Musenge E. The effects of progressive-resisted exercises on muscle strength and health-related quality of life in persons with HIV-related poly-neuropathy in Zimbabwe[J]. AIDS Care, 2016, 28(5):639-643.
[39] Sandoval R, Roddey T, Giordano TP, et al. Randomized trial of lower extremity splinting to manage neuropathic pain and sleep disturbances in people living with HIV/AIDS[J]. J Int Assoc Provid AIDS Care, 2016, 15(3):240-247.